<DOC>
	<DOC>NCT02001987</DOC>
	<brief_summary>This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of RoActemra/Actemra as a monotherapy or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with moderate to severe rheumatoid arthritis who have an inadequate response or are intolerant to non-biologic DMARDs or biologic therapy. 162 mg RoActemra/Actemra will be administered once a week by subcutaneous injection for up to 76 weeks.</brief_summary>
	<brief_title>A Study Of RoActemra/Actemra (Tocilizumab) in Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) or Biologic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Patients &gt; / = 18 years of age Patients with a diagnosis of active RA according to the revised ACR criteria or EULAR/ACR criteria and receiving outpatient treatment Oral corticosteroids (&lt; / = 10 mg/day prednisone or equivalent) nonsteroidal antiinflammatory drugs (NSAIDs), and permitted nonbiologic DMARDs are allowed if on a stable dose regimen for &gt; / = 20 mm/h and swollen joint count (SJC) &gt; / = 3 (based on 44 joints) Inadequate response (IR) to tumor necrosis factor, Abatacept and/or nonbiological diseasemodifying antirheumatic drugs (DMARDs) Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline Rheumatic autoimmune disease other than RA; Secondary Sj√∂gren's syndrome with RA is permitted. Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16 Prior history of current inflammatory joint disease other than RA Exposure to RoActemra/Actemra at any time prior to Baseline Treatment with any investigational agent within 4 weeks of Screening Previous treatment with any celldepleting therapies, including investigational agents or approved therapies or any alkylating agents such as chlorambucil, or with total lymphoid irradiation Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline Intraarticular or parenteral corticosteroids within 4 weeks prior to Baseline Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies Serious uncontrolled concomitant disease or other significant condition History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections Any infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening Active TB requiring treatment within the previous 3 years Positive for hepatitis B or C Primary or secondary immunodeficiency disorder Active cancer, or cancer diagnosed within the previous 10 years (except for nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated of excised and is considered resolved), or breast cancer diagnosed within the previous 20 years History of alcohol, drug, or chemical abuse within 1 year prior to Screening Neuropathies or other conditions that might interfere with pain evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>